The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its license arrangements. The dollar amounts in the tables below are in thousands.




	2003 Sandoz Agreement			2006 Sandoz Agreement			Mylan Collaboration Agreement			CSL Collaboration Agreement			Total
Contract assets
Collaboration receivables:
Opening - January 1, 2018	$	406		$	14,219		$	423		$	—		$	15,048
Revenue / cost recovery	7			42,145			550			—			$	42,702
Receipts	(413		)	(45,083		)	(883		)	—			$	(46,379	)
Ending - December 31, 2018	—			11,281			90			—			11,371

Contract liabilities
Deferred revenue:
Opening - January 1, 2018	—			—			39,128			—			39,128
Recognition of deferred revenue	—			—			(33,438		)	—			(33,438		)
Ending - December 31, 2018	—			—			5,690			—			5,690
Less: current portion	—			—			(3,916		)	—			(3,916		)
Deferred revenue, net of current portion - December 31, 2018	—			—			1,774			—			1,774

Collaboration liabilities:
Opening - January 1, 2018	—			—			8,245			1,013			9,258
Payments	—			—			—			(7,369		)	(7,369		)
Net collaboration costs incurred in the period	—			—			(6,833		)	9,665			2,832
Ending - December 31, 2018	$	—		$	—		$	1,412		$	3,309		$	4,721



	For the Year Ended December 31, 2018
	2003 Sandoz Agreement		2006 Sandoz Agreement		Mylan Collaboration Agreement			CSL Collaboration Agreement		Total
Product revenue	$	—	$	39,684	$	—		$	—	$	39,684
Research and development revenue	$	7	$	2,461	$	33,437		$	—	$	35,905
Total collaboration revenue	$	7	$	42,145	$	33,437		$	—	$	75,589
Operating expenses:
Research and development expense	$	—	$	826	$	25,932		$	875	$	27,633
General and administrative expense	$	13,709	$	152	$	1,978		$	31	$	15,870
Net amount (recovered from) / payable to collaborators	$	—	$	—	$	(7,383	)	$	9,665	$	2,282
Total operating expenses	$	13,709	$	978	$	20,527		$	10,571	$	45,785



	For the Year Ended December 31, 2017
	2003 Sandoz Agreement		2006 Sandoz Agreement		Mylan Collaboration Agreement			CSL Collaboration Agreement			Total
Product revenue	$	313	$	66,490	$	—		$	—		$	66,803
Research and development revenue	$	2,856	$	12,142	$	5,015		$	52,066		$	72,079
Total collaboration revenue	$	3,169	$	78,632	$	5,015		$	52,066		$	138,882
Operating expenses:
Research and development expense	$	1,958	$	1,766	$	62,049		$	8,179		$	73,952
General and administrative expense	$	15,426	$	494	$	3,617		$	124		$	19,661
Net amount (recovered from) collaborators	$	—	$	—	$	(25,835	)	$	(3,320	)	$	(29,155	)
Total operating expenses	$	17,384	$	2,260	$	39,831		$	4,983		$	64,458



	For the Year Ended December 31, 2016
	2003 Sandoz Agreement		2006 Sandoz Agreement		Mylan Collaboration Agreement			Baxalta Agreement		Total
Product revenue	$	—	$	74,648	$	—		$	—	$	74,648
Research and development revenue	$	345	$	2,545	$	6,368		$	25,713	$	34,971
Total collaboration revenue	$	345	$	77,193	$	6,368		$	25,713	$	109,619
Operating expenses:
Research and development expense	$	692	$	1,911	$	55,147		$	1,196	$	58,946
General and administrative expense	$	7	$	470	$	3,009		$	187	$	3,673
Net amount (recovered from) collaborators	$	—	$	—	$	(27,770	)	$	—	$	(27,770	)
Total operating expenses	$	699	$	2,381	$	30,386		$	1,383	$	34,849